PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29404485-7	2017	EV CYP2E1 amounts depended on increased oxidative and endoplasmic reticulum (ER) stress because their levels were decreased by cotreatment with the antioxidant N-acetylcysteine or the CYP2E1 inhibitor chlormethiazole but increased by ER stress-inducer thapsigargin, which was blocked by 4-phenylbutyric acid.	Chlormethiazole	201-216	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	3-9
31468699-10	2020	Our results showed that CMZ effectively restored the hepatic histopathological changes, oxidative stress biomarkers and TNF-alpha levels induced by APAP or TG.	Chlormethiazole	24-27	tumor necrosis factor	Rattus norvegicus	120-129
30641601-12	2019	First results on the effect of CYP2E1 inhibition by chlormethiazole, a specific CYP2E1 inhibitor on ALD, can be expected soon.	Chlormethiazole	52-67	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	31-37
30641601-12	2019	First results on the effect of CYP2E1 inhibition by chlormethiazole, a specific CYP2E1 inhibitor on ALD, can be expected soon.	Chlormethiazole	52-67	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	80-86
28987868-6	2018	Ethanol exposure resulted in increased levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)-Akt adducts, which was significantly inhibited by chlormethiazole (CMZ), an efficient CYP2E1 inhibitor.	Chlormethiazole	150-165	AKT serine/threonine kinase 1	Homo sapiens	100-103
28987868-6	2018	Ethanol exposure resulted in increased levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)-Akt adducts, which was significantly inhibited by chlormethiazole (CMZ), an efficient CYP2E1 inhibitor.	Chlormethiazole	150-165	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	186-192
28987868-6	2018	Ethanol exposure resulted in increased levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)-Akt adducts, which was significantly inhibited by chlormethiazole (CMZ), an efficient CYP2E1 inhibitor.	Chlormethiazole	167-170	AKT serine/threonine kinase 1	Homo sapiens	100-103
28987868-6	2018	Ethanol exposure resulted in increased levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)-Akt adducts, which was significantly inhibited by chlormethiazole (CMZ), an efficient CYP2E1 inhibitor.	Chlormethiazole	167-170	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	186-192
29120493-2	2018	Experimental data underline the key role of CYP2E1 because ALD could be partially prevented in rats by the administration of the specific CYP2E1 inhibitor chlormethiazole.	Chlormethiazole	155-170	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	44-50
29120493-2	2018	Experimental data underline the key role of CYP2E1 because ALD could be partially prevented in rats by the administration of the specific CYP2E1 inhibitor chlormethiazole.	Chlormethiazole	155-170	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	138-144
30362092-5	2018	Etheno-DNA adducts are generated in the liver (HepG2) cells over-expressing CYP2E1 when incubated with ethanol;and are inhibited by chlormethiazole.	Chlormethiazole	132-147	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	76-82
29404485-7	2017	EV CYP2E1 amounts depended on increased oxidative and endoplasmic reticulum (ER) stress because their levels were decreased by cotreatment with the antioxidant N-acetylcysteine or the CYP2E1 inhibitor chlormethiazole but increased by ER stress-inducer thapsigargin, which was blocked by 4-phenylbutyric acid.	Chlormethiazole	201-216	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	184-190
18414994-7	2008	The enhanced cytotoxicity could also be protected by treating rats with chlormethiazole, a specific inhibitor of CYP2E1, thus validating the role of CYP2E1.	Chlormethiazole	72-87	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	113-119
25162931-2	2014	The current study was designed to evaluate the effects of chlormethiazole (CMZ), a specific inhibitor of CYP2E1, on acute ethanol-induced fatty liver, and to explore the mechanisms.	Chlormethiazole	58-73	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	105-111
25162931-2	2014	The current study was designed to evaluate the effects of chlormethiazole (CMZ), a specific inhibitor of CYP2E1, on acute ethanol-induced fatty liver, and to explore the mechanisms.	Chlormethiazole	75-78	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	105-111
25162931-8	2014	Furthermore, a significant decline of p62 protein level was observed in CMZ/ethanol group mice liver compared with that of the ethanol group mice.	Chlormethiazole	72-75	nucleoporin 62	Mus musculus	38-41
25162931-10	2014	Collectively, the results of the current study demonstrated that CMZ could effectively attenuate acute ethanol-induced fatty liver possibly by suppressing oxidative stress and adiponectin decline, and activating autophagy, which suggest that CYP2E1 might also play important roles in acute ethanol-induced fatty liver.	Chlormethiazole	65-68	adiponectin, C1Q and collagen domain containing	Mus musculus	176-187
25162931-10	2014	Collectively, the results of the current study demonstrated that CMZ could effectively attenuate acute ethanol-induced fatty liver possibly by suppressing oxidative stress and adiponectin decline, and activating autophagy, which suggest that CYP2E1 might also play important roles in acute ethanol-induced fatty liver.	Chlormethiazole	65-68	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	242-248
24717297-4	2014	Chlormethiazole, a specific CYP2E1 transcription inhibitor, prevented an increase in catalytic iron in the kidneys, decreased oxidative stress, blocked nuclear translocation of the Nrf2 protein, decreased heme oxygenase-1 upregulation, and provided functional and histological protection against acute kidney injury.	Chlormethiazole	0-15	cytochrome P450 family 2 subfamily E member 1	Sus scrofa	28-34
24717297-4	2014	Chlormethiazole, a specific CYP2E1 transcription inhibitor, prevented an increase in catalytic iron in the kidneys, decreased oxidative stress, blocked nuclear translocation of the Nrf2 protein, decreased heme oxygenase-1 upregulation, and provided functional and histological protection against acute kidney injury.	Chlormethiazole	0-15	heme oxygenase 1	Sus scrofa	205-221
23543859-2	2012	We investigated whether treatment with chlormethiazole (CMZ), a CYP2E1 inhibitor, protects against alcohol-associated hepatic carcinogenesis in rats.	Chlormethiazole	39-54	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	64-70
23543859-2	2012	We investigated whether treatment with chlormethiazole (CMZ), a CYP2E1 inhibitor, protects against alcohol-associated hepatic carcinogenesis in rats.	Chlormethiazole	56-59	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	64-70
22042250-0	2012	Association between leptin levels and doses of clomethiazole during alcohol withdrawal: a pilot study.	Chlormethiazole	47-60	leptin	Homo sapiens	20-26
22042250-3	2012	The aim of the pilot study was to examine leptin levels in correlation with the strongly GABA-mimetic active substance clomethiazole.	Chlormethiazole	119-132	leptin	Homo sapiens	42-48
22042250-4	2012	The main hypothesis was that higher doses of the strong GABA-mimetic clomethiazole are positively correlated with higher leptin levels.	Chlormethiazole	69-82	leptin	Homo sapiens	121-127
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	16-29	leptin	Homo sapiens	81-87
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	16-29	leptin	Homo sapiens	158-164
28336091-5	2017	The CYP2E1 inhibitor chlormethiazole inhibited ROS generation, mitochondrial membrane potential loss, caspase-3 activity, and cytotoxicity caused by MC-LR.	Chlormethiazole	21-36	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	4-10
28336091-5	2017	The CYP2E1 inhibitor chlormethiazole inhibited ROS generation, mitochondrial membrane potential loss, caspase-3 activity, and cytotoxicity caused by MC-LR.	Chlormethiazole	21-36	caspase 3	Homo sapiens	102-111
27149898-0	2016	Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole.	Chlormethiazole	66-79	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	56-62
26739624-9	2016	In cells pretreated with the CYP2E1 inhibitor chlormethiazole, recovery of ATP was significantly higher in the presence of stearate with low (2.5mM) or high (20mM) concentrations of APAP.	Chlormethiazole	46-61	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	29-35
25427901-8	2015	ROS production correlates significantly with CYP2E1 in the liver but also in the esophagus, and its generation can be significantly reduced by the specific CYP2E1 inhibitor clomethiazole.	Chlormethiazole	173-186	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	45-51
25427901-8	2015	ROS production correlates significantly with CYP2E1 in the liver but also in the esophagus, and its generation can be significantly reduced by the specific CYP2E1 inhibitor clomethiazole.	Chlormethiazole	173-186	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	156-162
25162931-0	2014	Inhibition of cytochrome P4502E1 by chlormethiazole attenuated acute ethanol-induced fatty liver.	Chlormethiazole	36-51	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	14-32
24892905-2	2014	The current study was designed to evaluate whether CYP2E1 suppression by chlormethiazole (CMZ) could suppress AFL in mice, and to explore the underlying mechanisms.	Chlormethiazole	73-88	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	51-57
24892905-2	2014	The current study was designed to evaluate whether CYP2E1 suppression by chlormethiazole (CMZ) could suppress AFL in mice, and to explore the underlying mechanisms.	Chlormethiazole	90-93	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	51-57
24892905-9	2014	Chronic ethanol exposure led to significant decrease of the mRNA and protein levels of peroxisome proliferator-activated receptor alpha (PPAR-alpha), which was blocked by CMZ co-treatment.	Chlormethiazole	171-174	peroxisome proliferator activated receptor alpha	Mus musculus	87-135
24892905-9	2014	Chronic ethanol exposure led to significant decrease of the mRNA and protein levels of peroxisome proliferator-activated receptor alpha (PPAR-alpha), which was blocked by CMZ co-treatment.	Chlormethiazole	171-174	peroxisome proliferator activated receptor alpha	Mus musculus	137-147
24500986-7	2014	In PRA, CYP2E1-induced suppression of GLUT4 expression was blocked by chlormethiazole (CYP2E1-specific inhibitor) and the antioxidants vitamin E and N-acetyl-l-cysteine.	Chlormethiazole	70-85	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	8-14
24500986-7	2014	In PRA, CYP2E1-induced suppression of GLUT4 expression was blocked by chlormethiazole (CYP2E1-specific inhibitor) and the antioxidants vitamin E and N-acetyl-l-cysteine.	Chlormethiazole	70-85	solute carrier family 2 member 4	Rattus norvegicus	38-43
24500986-7	2014	In PRA, CYP2E1-induced suppression of GLUT4 expression was blocked by chlormethiazole (CYP2E1-specific inhibitor) and the antioxidants vitamin E and N-acetyl-l-cysteine.	Chlormethiazole	70-85	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	87-93
24064383-7	2013	All these changes, including the intestinal histology and hepatic apoptosis, determined by TUNEL assay, were significantly reversed when WT-EtOH mice were treated with the specific inhibitor of CYP2E1 chlormethiazole and the antioxidant N-acetylcysteine, both of which suppressed oxidative markers including intestinal CYP2E1.	Chlormethiazole	201-216	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	194-200
23421770-2	2013	METHODS: Sprague-Dawley rats were fed a liquid ethanol diet, control diet or ethanol diet supplemented with CYP2E1 inhibitor, chlormethiazole (CMZ), for 4 weeks.	Chlormethiazole	126-141	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	108-114
23421770-10	2013	In cultured Kupffer cells, increased CYP2E1 content and ROS production by in vitro ethanol induction were dose-dependently inhibited by CMZ.	Chlormethiazole	136-139	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	37-43
23400919-11	2013	We have shown that chlormethiazole is a specific CYP2E1 inhibitor in humans.	Chlormethiazole	19-34	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	49-55
23400919-12	2013	Chlormethiazole inhibits CYP2E1 activity and thus blocks the formation of DNA adducts in cell cultures, restores retinoic acids in alcohol fed animals and inhibits chemical induced ethanol mediated hepatocarcinogenesis.	Chlormethiazole	0-15	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	25-31
22819980-10	2012	The antioxidant N-acetylcysteine, and CYP2E1 inhibitor chlormethiazole blunted these effects of ethanol.	Chlormethiazole	55-70	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	38-44
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	16-29	leptin	Homo sapiens	158-164
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	108-121	leptin	Homo sapiens	81-87
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	108-121	leptin	Homo sapiens	81-87
22042250-8	2012	RESULTS: In the clomethiazole group, significant correlations were found between leptin levels at day 1 and clomethiazole dose (p = 0.004), clomethiazole and leptin at day 1/BMI (p = 0.009) and leptin at day 1 and clomethiazole/body surface (p = 0.006).	Chlormethiazole	108-121	leptin	Homo sapiens	81-87
22042250-9	2012	Furthermore, patients with higher clomethiazole doses demonstrated significant higher leptin levels at day 1 (p = 0.044) and day 7 (p = 0.046).	Chlormethiazole	34-47	leptin	Homo sapiens	86-92
22042250-10	2012	CONCLUSIONS: Our pilot data show a strong association between leptin levels and clomethiazole doses, thus supporting further research.	Chlormethiazole	80-93	leptin	Homo sapiens	62-68
18414994-7	2008	The enhanced cytotoxicity could also be protected by treating rats with chlormethiazole, a specific inhibitor of CYP2E1, thus validating the role of CYP2E1.	Chlormethiazole	72-87	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	149-155
18651341-6	2008	RESULTS: Cox regression revealed a lower risk of premature discharge being significantly asso-ciated with few preceding withdrawals, intoxication at admission and treatment with clomethiazole.	Chlormethiazole	178-191	cytochrome c oxidase subunit 8A	Homo sapiens	9-12
17963120-7	2007	In addition, CYP2E1 inhibitors chlormethiazole and diallyl dulphide inhibited both ROS generation and cytotoxicity induced by MCLR.	Chlormethiazole	31-46	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	13-19
18393316-8	2008	Chlormethiazole, an inhibitor of CYP2E1, lowered macrovesicular fat accumulation, inhibited oxidative stress, and up-regulated PPARalpha protein level in wild-type mice fed ethanol.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	33-39
18393316-8	2008	Chlormethiazole, an inhibitor of CYP2E1, lowered macrovesicular fat accumulation, inhibited oxidative stress, and up-regulated PPARalpha protein level in wild-type mice fed ethanol.	Chlormethiazole	0-15	peroxisome proliferator activated receptor alpha	Mus musculus	127-136
17538970-9	2007	The CYP2E1 inhibitor chlormethiazole and iNOS inhibitor N-(3-(aminomethyl)-benzyl) acetamidine abrogated the toxicity and the oxidative/nitrosative stress elicited by the induction of CYP2E1.	Chlormethiazole	21-36	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	4-10
17640612-6	2007	The cytotoxicity was prevented by treating rats with chlormethiazole, a specific inhibitor of CYP2E1.	Chlormethiazole	53-68	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	94-100
17538970-9	2007	The CYP2E1 inhibitor chlormethiazole and iNOS inhibitor N-(3-(aminomethyl)-benzyl) acetamidine abrogated the toxicity and the oxidative/nitrosative stress elicited by the induction of CYP2E1.	Chlormethiazole	21-36	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	184-190
14530209-12	2003	Chlormethiazole produced weak nonselective inhibition of human NMDA NR1a+NR2A and NR1a+NR2B receptors.	Chlormethiazole	0-15	glutamate ionotropic receptor NMDA type subunit 2A	Homo sapiens	73-77
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	interleukin 1 alpha	Rattus norvegicus	48-57
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	interleukin 1 beta	Rattus norvegicus	59-67
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	tumor necrosis factor	Rattus norvegicus	69-78
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	colony stimulating factor 2	Rattus norvegicus	83-89
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	interleukin 4	Rattus norvegicus	121-125
17112678-12	2007	Treatment with CMZ ameliorated the increases in IL-1alpha, IL-1beta, TNF-alpha and GM-CSF levels while increasing plasma IL-4 and IL-10 levels.	Chlormethiazole	15-18	interleukin 10	Rattus norvegicus	130-135
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	27-42	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	74-80
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	27-42	lactoperoxidase	Homo sapiens	118-121
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	27-42	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	123-129
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	27-42	mitogen-activated protein kinase 8	Homo sapiens	131-134
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	44-47	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	74-80
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	44-47	lactoperoxidase	Homo sapiens	118-121
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	44-47	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	123-129
16963249-8	2007	However, pretreatment with chlormethiazole (CMZ), a specific inhibitor of CYP2E1, significantly reduced the levels of LPO, CYP2E1, JNK activity and the rate of cell death.	Chlormethiazole	44-47	mitogen-activated protein kinase 8	Homo sapiens	131-134
16330492-10	2006	Pretreatment with chlormethiazole, an inhibitor of ethanol-inducible CYP2E1, significantly lowered the CYP2E1 enzyme activity and the rate of APAP-induced cell death while it prevented the reduction of p53 and p21 in C6 glioma cells.	Chlormethiazole	18-33	cytochrome P450 family 2 subfamily E member 1	Sus scrofa	69-75
16330492-10	2006	Pretreatment with chlormethiazole, an inhibitor of ethanol-inducible CYP2E1, significantly lowered the CYP2E1 enzyme activity and the rate of APAP-induced cell death while it prevented the reduction of p53 and p21 in C6 glioma cells.	Chlormethiazole	18-33	cytochrome P450 family 2 subfamily E member 1	Sus scrofa	103-109
16330492-10	2006	Pretreatment with chlormethiazole, an inhibitor of ethanol-inducible CYP2E1, significantly lowered the CYP2E1 enzyme activity and the rate of APAP-induced cell death while it prevented the reduction of p53 and p21 in C6 glioma cells.	Chlormethiazole	18-33	tumor protein p53	Sus scrofa	202-205
16025513-12	2005	Administration of chlormethiazole, an inhibitor of CYP2E1, to the Pyr/Jo2-treated mice caused a significant decrease of alanine aminotransferase and liver pathological changes in association with a decrease in CYP2E1 protein and activity.	Chlormethiazole	18-33	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	51-57
16025513-12	2005	Administration of chlormethiazole, an inhibitor of CYP2E1, to the Pyr/Jo2-treated mice caused a significant decrease of alanine aminotransferase and liver pathological changes in association with a decrease in CYP2E1 protein and activity.	Chlormethiazole	18-33	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	210-216
14530209-12	2003	Chlormethiazole produced weak nonselective inhibition of human NMDA NR1a+NR2A and NR1a+NR2B receptors.	Chlormethiazole	0-15	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	87-91
12895459-7	2003	Clomethiazole significantly attenuated CA1 cell loss at 10-, 30-, and 60-day survival.	Chlormethiazole	0-13	carbonic anhydrase 1	Homo sapiens	39-42
12895459-11	2003	Based on short-term CA1 cell counts, clomethiazole provided significant histological protection with limited functional preservation.	Chlormethiazole	37-50	carbonic anhydrase 1	Homo sapiens	20-23
12359265-5	2002	Clomethiazole directly activated GABA(A) currents in alpha1/beta1/gamma 2- and alpha1/beta2/gamma 2-containing cells, with EC(50) values of 0.3 and 1.5 mM, respectively.	Chlormethiazole	0-13	adrenoceptor alpha 1D	Homo sapiens	53-85
12436060-2	2002	This study investigated whether treatment with chlormethiazole, a CYP inhibitor, restores vitamin A in the livers of ethanol-fed rats.	Chlormethiazole	47-62	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	66-69
12359265-5	2002	Clomethiazole directly activated GABA(A) currents in alpha1/beta1/gamma 2- and alpha1/beta2/gamma 2-containing cells, with EC(50) values of 0.3 and 1.5 mM, respectively.	Chlormethiazole	0-13	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	86-97
10425374-7	1999	Good agreement was found when the resulting Kbl/w vs. pH curves for CMZ, lidocaine and prilocaine were fitted to a mathematical expression.	Chlormethiazole	68-71	glycine C-acetyltransferase	Homo sapiens	44-47
11591835-0	2001	The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.	Chlormethiazole	4-17	plasminogen activator, tissue type	Homo sapiens	40-73
11208727-5	2001	In vivo, both ethanol-exposed and non-ethanol-exposed rats were treated with or without chlormethiazole, a specific CYP2E1 inhibitor, for 1 month.	Chlormethiazole	88-103	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	116-122
11133247-2	2001	Certain drugs such as the sedative chlormethiazole are effective inhibitors of CYP2E1, and may have clinical potential in the treatment of alcoholics.	Chlormethiazole	35-50	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	79-85
10964266-5	2000	The CYP2E1 apoprotein levels, which were increased by ethanol feeding, were also increased when chlormethiazole was fed with ethanol.	Chlormethiazole	96-111	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	4-10
10964266-6	2000	Chlormethiazole inhibited the increase in the ethanol-induced CYP2E1 activity in vivo, as measured by chlorzoxazone 6-hydroxylation, but did not affect the level of CYP2E1 apoprotein.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	62-68
10908041-3	2000	Here the authors suggested that chlormethiazole has anti-inflammatory properties because it potently and selectively inhibited p38 mitogen-activated protein (MAP) kinase in primary cortical glial cultures.	Chlormethiazole	32-47	mitogen-activated protein kinase 14	Homo sapiens	127-130
10964266-8	2000	These results support the conclusion that chlormethiazole treatment partially protects the liver from injury by inhibiting CYP2E1 activity in vivo.	Chlormethiazole	42-57	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	123-129
10412797-14	1999	MAP2 staining showed that, compared to uninjured controls, grey matter was reduced to 7.4 +/- 2.7% in saline-treated injured animals and to 22.7 +/- 5.4% in CMZ-treated rats.	Chlormethiazole	157-160	microtubule-associated protein 2	Rattus norvegicus	0-4
10461422-3	1999	Recently, chlormethiazole a sedative drug, is reported to be an efficient inhibitor of CYP2E1 activity in human beings.	Chlormethiazole	10-25	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	87-93
10461422-4	1999	In this study we wished to evaluate whether chlormethiazole, an inhibitor of CYP2E1, could prevent acetaminophen-induced liver injury in mice.	Chlormethiazole	44-59	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	77-83
10461422-8	1999	RESULTS: Pretreatment with chlormethiazole 30 min before 400 mg/kg of acetaminophen completely inhibited acetaminophen-induced liver injury (median 118.5 U/L, range 75 to 142 vs. 14,070 U/L, range 5980 to 27,680 for AST; 49 U/L, range 41 to 64 vs. 15,330 U/L, range 13,920 to 15,940 for ALT).	Chlormethiazole	27-42	transmembrane protease, serine 11d	Mus musculus	216-219
10461422-8	1999	RESULTS: Pretreatment with chlormethiazole 30 min before 400 mg/kg of acetaminophen completely inhibited acetaminophen-induced liver injury (median 118.5 U/L, range 75 to 142 vs. 14,070 U/L, range 5980 to 27,680 for AST; 49 U/L, range 41 to 64 vs. 15,330 U/L, range 13,920 to 15,940 for ALT).	Chlormethiazole	27-42	glutamic pyruvic transaminase, soluble	Mus musculus	287-290
10461422-9	1999	In mice receiving chlormethiazole 2 h after acetaminophen, the mean AST and ALT levels were also less elevated, reaching only 20% of the value of acetaminophen-only group.	Chlormethiazole	18-33	transmembrane protease, serine 11d	Mus musculus	68-71
10461422-9	1999	In mice receiving chlormethiazole 2 h after acetaminophen, the mean AST and ALT levels were also less elevated, reaching only 20% of the value of acetaminophen-only group.	Chlormethiazole	18-33	glutamic pyruvic transaminase, soluble	Mus musculus	76-79
9927612-5	1999	Anti-CYP2E1 reactivity showed positive correlation with the levels of hepatic CYP2E1 and was inhibited by the CYP2E1 transcriptional inhibitor chlormethiazole.	Chlormethiazole	143-158	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	5-11
10195555-5	1999	The symptoms of AWS can be controlled using the combination of a benzodiazepine (in Europe, also chlormethiazole) with haloperidol or clonidine.	Chlormethiazole	97-112	jagged canonical Notch ligand 1	Homo sapiens	16-19
9927612-5	1999	Anti-CYP2E1 reactivity showed positive correlation with the levels of hepatic CYP2E1 and was inhibited by the CYP2E1 transcriptional inhibitor chlormethiazole.	Chlormethiazole	143-158	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	78-84
9927612-5	1999	Anti-CYP2E1 reactivity showed positive correlation with the levels of hepatic CYP2E1 and was inhibited by the CYP2E1 transcriptional inhibitor chlormethiazole.	Chlormethiazole	143-158	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	78-84
17895123-0	1998	The clomethiazole acute stroke study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a phase III trial in the united states and canada.	Chlormethiazole	4-17	plasminogen activator, tissue type	Homo sapiens	67-71
8566181-4	1995	In contrast to alpha 1 beta 3 gamma 2 receptors, however, [3H]flunitrazepam binding to recombinant alpha 1 gamma 2 receptors was inhibited by pentobarbital, (+)-etomidate, etazolate, alphaxalone, propofol and chlormethiazole.	Chlormethiazole	209-224	adrenoceptor alpha 1D	Homo sapiens	99-106
9695719-0	1998	Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.	Chlormethiazole	24-39	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	14-20
9695719-1	1998	BACKGROUND: Chlormethiazole has been shown in in vitro studies, with use of rat and human liver microsomes, to specifically inhibit cytochrome P4502E1 (CYP2E1)-mediated activity by inhibition of the rate of CYP2E1 gene transcription.	Chlormethiazole	12-27	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	132-150
9695719-1	1998	BACKGROUND: Chlormethiazole has been shown in in vitro studies, with use of rat and human liver microsomes, to specifically inhibit cytochrome P4502E1 (CYP2E1)-mediated activity by inhibition of the rate of CYP2E1 gene transcription.	Chlormethiazole	12-27	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	152-158
9695719-1	1998	BACKGROUND: Chlormethiazole has been shown in in vitro studies, with use of rat and human liver microsomes, to specifically inhibit cytochrome P4502E1 (CYP2E1)-mediated activity by inhibition of the rate of CYP2E1 gene transcription.	Chlormethiazole	12-27	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	207-213
9695719-7	1998	CONCLUSION: Chlormethiazole administration seems to result in a marked reduction of CYP2E1 activity in subjects with high CYP2E1 activity and could at least partially explain the claimed hepatoprotective action of this drug.	Chlormethiazole	12-27	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	84-90
9695719-7	1998	CONCLUSION: Chlormethiazole administration seems to result in a marked reduction of CYP2E1 activity in subjects with high CYP2E1 activity and could at least partially explain the claimed hepatoprotective action of this drug.	Chlormethiazole	12-27	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	122-128
9581684-0	1998	Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole.	Chlormethiazole	111-126	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	80-99
9581684-3	1998	We investigated zonal differences of cytokine expression in rat liver and how these are affected by alcohol exposure and by chlormethiazole (CMZ), a transcriptional and posttranslational inhibitor of hepatic CYP2E1.	Chlormethiazole	124-139	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	208-214
9581684-3	1998	We investigated zonal differences of cytokine expression in rat liver and how these are affected by alcohol exposure and by chlormethiazole (CMZ), a transcriptional and posttranslational inhibitor of hepatic CYP2E1.	Chlormethiazole	141-144	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	208-214
9398454-3	1997	Chlormethiazole attenuated the loss of neurones in the hippocampal cell layers CA1 (cell loss 10 +/- 3.2%) and CA3a (cell loss 10 +/- 7.7%).	Chlormethiazole	0-15	carbonic anhydrase 1	Rattus norvegicus	79-82
8863515-7	1996	Chlormethiazole, a potent inhibitor of hepatic CYP2E1 transcription, inhibited the ethanol-dependent induction of CYP2E1 by 50%.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	47-53
8863515-7	1996	Chlormethiazole, a potent inhibitor of hepatic CYP2E1 transcription, inhibited the ethanol-dependent induction of CYP2E1 by 50%.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	114-120
9328319-0	1997	Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans.	Chlormethiazole	0-15	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	30-49
9328319-2	1997	Because it had been reported that chlormethiazole inhibits the alcohol-inducible cytochrome P450 2E1 in rat liver, we investigated the in vivo and in vitro effect of this drug on cytochrome P450 2E1 in human beings.	Chlormethiazole	34-49	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	81-100
9328319-10	1997	In addition, the effect of chlormethiazole on cytochrome P450 2E1 was studied in vitro using human liver microsomes.	Chlormethiazole	27-42	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	46-65
9328319-12	1997	These data clearly show that chlormethiazole is an efficient inhibitor of chlorzoxazone metabolism and thus of cytochrome P450 2E1 activity in human beings.	Chlormethiazole	29-44	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	111-130
9328319-13	1997	Because cytochrome P450 2E1 induction after chronic ethanol consumption has detrimental effects on the liver through free radical formation, treatment of alcohol detoxification with chlormethiazole may be beneficial.	Chlormethiazole	182-197	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	8-27
8913336-5	1996	Chlormethiazole, a specific inhibitor of hepatic CYP2E1 transcription, completely inhibited the induction of CYP2E1 at the mRNA and enzyme levels.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	49-55
8913336-5	1996	Chlormethiazole, a specific inhibitor of hepatic CYP2E1 transcription, completely inhibited the induction of CYP2E1 at the mRNA and enzyme levels.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	109-115
7599932-9	1995	Chlormethiazole (930 mumol kg-1) was then infused intravenously for 30 min, 76.5 min or 110 min in ways resulting in sustained plasma concentrations of 200, 100 and 50 nmol ml-1 respectively.	Chlormethiazole	0-15	interleukin 17F	Homo sapiens	173-177
7599932-11	1995	There was a dose-dependent decline in protection when plasma chlormethiazole concentrations of 50, 30 and 10 nmol ml-1 were sustained for 110 min with no protection observed at 10 nmol ml-1.	Chlormethiazole	61-76	interleukin 17F	Homo sapiens	114-118
33972357-0	2022	Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.	Chlormethiazole	0-13	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	23-42
7870940-0	1993	Effect of chlormethiazole, dizocilpine and pentobarbital on harmaline-induced increase of cerebellar cyclic GMP and tremor.	Chlormethiazole	10-25	5'-nucleotidase, cytosolic II	Mus musculus	108-111
7870940-5	1993	They also demonstrate that chlormethiazole is able to inhibit a biochemical response (the increase in cerebellar cyclic GMP) which results from increased glutamate function.	Chlormethiazole	27-42	5'-nucleotidase, cytosolic II	Mus musculus	120-123
8014872-0	1994	Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver.	Chlormethiazole	0-15	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	45-64
8453968-1	1993	Chlormethiazole is a strong inhibitor of cytochrome P-450-dependent monooxygenases in isolated human liver microsomes.	Chlormethiazole	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
2544811-1	1989	Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans.	Chlormethiazole	0-13	prolactin	Homo sapiens	104-113
34758665-3	2021	Our study aimed to investigate the mechanisms of hepatotoxicity treated with TP in vivo and in vitro, as well as their relationship with the NF-kappaB (p65) signal pathway; and to assess TP-induced hepatotoxicity after CYP2E1 modulation by the known inhibitor, clomethiazole, and the known inducer, pyrazole.	Chlormethiazole	261-274	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	219-225
34110802-9	2021	A function verification study proved that chlormethiazole, a widely used CYP2E1 inhibitor, could reduce the production of indoxyl sulfate in the liver and attenuate cisplatin-induced AKI in rats.	Chlormethiazole	42-57	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	73-79
2544811-1	1989	Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans.	Chlormethiazole	0-13	prolactin	Homo sapiens	115-118
2544811-1	1989	Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans.	Chlormethiazole	15-19	prolactin	Homo sapiens	104-113
2544811-1	1989	Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans.	Chlormethiazole	15-19	prolactin	Homo sapiens	115-118
2544811-5	1989	In vitro, the inhibitory effect of muscimol on PRL release from rat hemiadenohypophysis was potentiated in a dose-dependent manner by preincubation with CLOM.	Chlormethiazole	153-157	prolactin	Rattus norvegicus	47-50
3479154-6	1987	Contractions induced by angiotensin II were inhibited by thiopentone 10(-3) mol litre-1 and chlormethiazole 3 x 10(-3) mol litre-1.	Chlormethiazole	92-107	angiotensinogen	Homo sapiens	24-38
709310-0	1978	Effect of chlormethiazole on serum prolactin.	Chlormethiazole	10-25	prolactin	Homo sapiens	35-44
659564-0	1978	Analysis of chlormethiazole, ethchlorvynol and trichloroethanol in biological fluids by gas-liquid chromatography as an aid to the diagnosis of acute poisoning.	Chlormethiazole	12-27	activation induced cytidine deaminase	Homo sapiens	120-123
3593489-0	1987	Selective inhibition of monoamine oxidase type B by chlormethiazole.	Chlormethiazole	52-67	monoamine oxidase B	Homo sapiens	24-48
4005096-1	1985	The cardiovascular effects of an infusion of chlormethiazole 30-40 ml min-1 were studied in six patients following an extradural injection of 2% lignocaine.	Chlormethiazole	45-60	CD59 molecule (CD59 blood group)	Homo sapiens	70-75
6476347-4	1984	A loading infusion of 5 ml X min-1 of the chlormethiazole solution was followed by a variable rate of infusion in order to maintain a predetermined state of sedation--i.e. where the patient lapsed into sleep but was easily awakened to obey commands.	Chlormethiazole	42-57	CD59 molecule (CD59 blood group)	Homo sapiens	29-34
7326165-7	1981	A high total body clearance of chlormethiazole (mean 1.39 litre min-1, SD 0.58) was found and would contribute to the brief duration of action after termination of the infusion.	Chlormethiazole	31-46	CD59 molecule (CD59 blood group)	Homo sapiens	64-69